FDA has come up with an estimate of the burden of creating monitoring plans as called for in its draft guidance on the oversight of clinical investigations, which recommends that sponsors develop a prospective, detailed plan that describes the monitoring methods, responsibilities and requirements for each clinical trial.
The agency expects that 88 sponsors will develop approximately 132 comprehensive monitoring plans annually and that it will take approximately...